Fluconazole

Cerebral Cryptococcosis, Candidemia, Coccidioidomycosis + 22 more

Treatment

24 FDA approvals

20 Active Studies for Fluconazole

What is Fluconazole

Fluconazole

The Generic name of this drug

Treatment Summary

Fluconazole, also known as Diflucan, is an antifungal medication used to treat fungal infections in different parts of the body. It was approved by the FDA in 1990 and belongs to the same drug family as ketoconazole and itraconazole. Fluconazole offers the advantage of being taken orally and has a low risk of side effects. It is very effective and is often prescribed as a single dose to treat vaginal yeast infections.

Diflucan

is the brand name

image of different drug pills on a surface

Fluconazole Overview & Background

Brand Name

Generic Name

First FDA Approval

How many FDA approvals?

Diflucan

Fluconazole

1990

379

Approved as Treatment by the FDA

Fluconazole, also called Diflucan, is approved by the FDA for 24 uses which include Candida pneumonia and Candida (fungus) .

Candida pneumonia

Candida (fungus)

Vaginal Candidiasis

Used to treat Vaginal Candidiasis in combination with Miconazole

Pruritus

Used to treat Pruritus in combination with Miconazole

Candidiasis

Systemic candidiasis

Meningitis, Cryptococcal

Coccidioidomycosis

Oropharyngeal Candidiasis

Candida urinary tract infection

Itching

Used to treat Pruritus in combination with Miconazole

Candidiasis, Vulvovaginal

Used to treat Vaginal Candidiasis in combination with Miconazole

Coccidioidomycosis

Urinary tract infection

Candida (fungus)

Peritonitis

Esophageal Candidiasis

Cerebral Cryptococcosis

Yeast Infection

Bone marrow transplant, cytotoxic chemotherapy

Candidemia

Bone Marrow Transplantation

Candidiasis

prophylaxis of Candida Infections

Effectiveness

How Fluconazole Affects Patients

Fluconazole is a medication used to treat fungal infections caused by Candida albicans, Candida glabrata, Candida parapsilosis, Candida tropicalis, and Cryptococcus neoformans. It works by blocking the growth and spread of fungi by interfering with cell wall synthesis and cell adhesion. However, some strains of these fungi have become resistant to fluconazole, which is why it is important to do susceptibility tests before taking the medication. While there have been concerns that fluconazole may affect human hormones, studies have not found any significant effects when taking up to 400 mg

How Fluconazole works in the body

Fluconazole is a drug that interferes with the growth of fungi. It does this by blocking an enzyme that helps create an important part of the fungal cell wall. When this enzyme is blocked, the fungi can't build the cell wall and so it can't grow. Some fungi have developed resistance to this drug, either by changing the amount of the enzyme or by changing the way it works.

When to interrupt dosage

The proposed measure of Fluconazole is contingent upon the diagnosed condition, including Candida (fungus), Candida intertrigo and Bone Marrow Transplantation. The dosage can be located in the table beneath, predicated on the technique of delivery (e.g. Topical or Powder, for solution).

Condition

Dosage

Administration

Solid Organ Transplant

, 4.0 mg/mL, 10.0 mg/mL, 40.0 mg/mL, 2.0 mg/mL, 50.0 mg, 100.0 mg, 150.0 mg, 200.0 mg, 35.0 mg/mL, 140.0 mg/mL, 0.04 mg/mg, 0.01 mg/mg, 50.0 mg/mL

, Injection, solution, Intravenous, Injection, solution - Intravenous, Oral, Powder, for suspension - Oral, Powder, for suspension, Injection, Injection - Intravenous, Tablet, Tablet - Oral, Capsule, Capsule - Oral, Solution - Intravenous, Solution, Capsule; Cream - Oral; Topical; Vaginal, Oral; Topical; Vaginal, Capsule; Cream, Oral; Topical, Capsule; Cream; Kit - Oral; Topical, Capsule; Cream; Kit, Powder, for solution, Powder, for solution - Oral, Solution - Oral, Solution - Topical, Topical, Capsule; Cream - Oral; Topical

Candidiasis

, 4.0 mg/mL, 10.0 mg/mL, 40.0 mg/mL, 2.0 mg/mL, 50.0 mg, 100.0 mg, 150.0 mg, 200.0 mg, 35.0 mg/mL, 140.0 mg/mL, 0.04 mg/mg, 0.01 mg/mg, 50.0 mg/mL

, Injection, solution, Intravenous, Injection, solution - Intravenous, Oral, Powder, for suspension - Oral, Powder, for suspension, Injection, Injection - Intravenous, Tablet, Tablet - Oral, Capsule, Capsule - Oral, Solution - Intravenous, Solution, Capsule; Cream - Oral; Topical; Vaginal, Oral; Topical; Vaginal, Capsule; Cream, Oral; Topical, Capsule; Cream; Kit - Oral; Topical, Capsule; Cream; Kit, Powder, for solution, Powder, for solution - Oral, Solution - Oral, Solution - Topical, Topical, Capsule; Cream - Oral; Topical

Candidiasis, Vulvovaginal

, 4.0 mg/mL, 10.0 mg/mL, 40.0 mg/mL, 2.0 mg/mL, 50.0 mg, 100.0 mg, 150.0 mg, 200.0 mg, 35.0 mg/mL, 140.0 mg/mL, 0.04 mg/mg, 0.01 mg/mg, 50.0 mg/mL

, Injection, solution, Intravenous, Injection, solution - Intravenous, Oral, Powder, for suspension - Oral, Powder, for suspension, Injection, Injection - Intravenous, Tablet, Tablet - Oral, Capsule, Capsule - Oral, Solution - Intravenous, Solution, Capsule; Cream - Oral; Topical; Vaginal, Oral; Topical; Vaginal, Capsule; Cream, Oral; Topical, Capsule; Cream; Kit - Oral; Topical, Capsule; Cream; Kit, Powder, for solution, Powder, for solution - Oral, Solution - Oral, Solution - Topical, Topical, Capsule; Cream - Oral; Topical

Urinary tract infection

, 4.0 mg/mL, 10.0 mg/mL, 40.0 mg/mL, 2.0 mg/mL, 50.0 mg, 100.0 mg, 150.0 mg, 200.0 mg, 35.0 mg/mL, 140.0 mg/mL, 0.04 mg/mg, 0.01 mg/mg, 50.0 mg/mL

, Injection, solution, Intravenous, Injection, solution - Intravenous, Oral, Powder, for suspension - Oral, Powder, for suspension, Injection, Injection - Intravenous, Tablet, Tablet - Oral, Capsule, Capsule - Oral, Solution - Intravenous, Solution, Capsule; Cream - Oral; Topical; Vaginal, Oral; Topical; Vaginal, Capsule; Cream, Oral; Topical, Capsule; Cream; Kit - Oral; Topical, Capsule; Cream; Kit, Powder, for solution, Powder, for solution - Oral, Solution - Oral, Solution - Topical, Topical, Capsule; Cream - Oral; Topical

Communicable Diseases

, 4.0 mg/mL, 10.0 mg/mL, 40.0 mg/mL, 2.0 mg/mL, 50.0 mg, 100.0 mg, 150.0 mg, 200.0 mg, 35.0 mg/mL, 140.0 mg/mL, 0.04 mg/mg, 0.01 mg/mg, 50.0 mg/mL

, Injection, solution, Intravenous, Injection, solution - Intravenous, Oral, Powder, for suspension - Oral, Powder, for suspension, Injection, Injection - Intravenous, Tablet, Tablet - Oral, Capsule, Capsule - Oral, Solution - Intravenous, Solution, Capsule; Cream - Oral; Topical; Vaginal, Oral; Topical; Vaginal, Capsule; Cream, Oral; Topical, Capsule; Cream; Kit - Oral; Topical, Capsule; Cream; Kit, Powder, for solution, Powder, for solution - Oral, Solution - Oral, Solution - Topical, Topical, Capsule; Cream - Oral; Topical

Yeast Infection

, 4.0 mg/mL, 10.0 mg/mL, 40.0 mg/mL, 2.0 mg/mL, 50.0 mg, 100.0 mg, 150.0 mg, 200.0 mg, 35.0 mg/mL, 140.0 mg/mL, 0.04 mg/mg, 0.01 mg/mg, 50.0 mg/mL

, Injection, solution, Intravenous, Injection, solution - Intravenous, Oral, Powder, for suspension - Oral, Powder, for suspension, Injection, Injection - Intravenous, Tablet, Tablet - Oral, Capsule, Capsule - Oral, Solution - Intravenous, Solution, Capsule; Cream - Oral; Topical; Vaginal, Oral; Topical; Vaginal, Capsule; Cream, Oral; Topical, Capsule; Cream; Kit - Oral; Topical, Capsule; Cream; Kit, Powder, for solution, Powder, for solution - Oral, Solution - Oral, Solution - Topical, Topical, Capsule; Cream - Oral; Topical

Bone Marrow Transplantation

, 4.0 mg/mL, 10.0 mg/mL, 40.0 mg/mL, 2.0 mg/mL, 50.0 mg, 100.0 mg, 150.0 mg, 200.0 mg, 35.0 mg/mL, 140.0 mg/mL, 0.04 mg/mg, 0.01 mg/mg, 50.0 mg/mL

, Injection, solution, Intravenous, Injection, solution - Intravenous, Oral, Powder, for suspension - Oral, Powder, for suspension, Injection, Injection - Intravenous, Tablet, Tablet - Oral, Capsule, Capsule - Oral, Solution - Intravenous, Solution, Capsule; Cream - Oral; Topical; Vaginal, Oral; Topical; Vaginal, Capsule; Cream, Oral; Topical, Capsule; Cream; Kit - Oral; Topical, Capsule; Cream; Kit, Powder, for solution, Powder, for solution - Oral, Solution - Oral, Solution - Topical, Topical, Capsule; Cream - Oral; Topical

Oropharyngeal Candidiasis

, 4.0 mg/mL, 10.0 mg/mL, 40.0 mg/mL, 2.0 mg/mL, 50.0 mg, 100.0 mg, 150.0 mg, 200.0 mg, 35.0 mg/mL, 140.0 mg/mL, 0.04 mg/mg, 0.01 mg/mg, 50.0 mg/mL

, Injection, solution, Intravenous, Injection, solution - Intravenous, Oral, Powder, for suspension - Oral, Powder, for suspension, Injection, Injection - Intravenous, Tablet, Tablet - Oral, Capsule, Capsule - Oral, Solution - Intravenous, Solution, Capsule; Cream - Oral; Topical; Vaginal, Oral; Topical; Vaginal, Capsule; Cream, Oral; Topical, Capsule; Cream; Kit - Oral; Topical, Capsule; Cream; Kit, Powder, for solution, Powder, for solution - Oral, Solution - Oral, Solution - Topical, Topical, Capsule; Cream - Oral; Topical

Esophageal Candidiasis

, 4.0 mg/mL, 10.0 mg/mL, 40.0 mg/mL, 2.0 mg/mL, 50.0 mg, 100.0 mg, 150.0 mg, 200.0 mg, 35.0 mg/mL, 140.0 mg/mL, 0.04 mg/mg, 0.01 mg/mg, 50.0 mg/mL

, Injection, solution, Intravenous, Injection, solution - Intravenous, Oral, Powder, for suspension - Oral, Powder, for suspension, Injection, Injection - Intravenous, Tablet, Tablet - Oral, Capsule, Capsule - Oral, Solution - Intravenous, Solution, Capsule; Cream - Oral; Topical; Vaginal, Oral; Topical; Vaginal, Capsule; Cream, Oral; Topical, Capsule; Cream; Kit - Oral; Topical, Capsule; Cream; Kit, Powder, for solution, Powder, for solution - Oral, Solution - Oral, Solution - Topical, Topical, Capsule; Cream - Oral; Topical

Candidemia

, 4.0 mg/mL, 10.0 mg/mL, 40.0 mg/mL, 2.0 mg/mL, 50.0 mg, 100.0 mg, 150.0 mg, 200.0 mg, 35.0 mg/mL, 140.0 mg/mL, 0.04 mg/mg, 0.01 mg/mg, 50.0 mg/mL

, Injection, solution, Intravenous, Injection, solution - Intravenous, Oral, Powder, for suspension - Oral, Powder, for suspension, Injection, Injection - Intravenous, Tablet, Tablet - Oral, Capsule, Capsule - Oral, Solution - Intravenous, Solution, Capsule; Cream - Oral; Topical; Vaginal, Oral; Topical; Vaginal, Capsule; Cream, Oral; Topical, Capsule; Cream; Kit - Oral; Topical, Capsule; Cream; Kit, Powder, for solution, Powder, for solution - Oral, Solution - Oral, Solution - Topical, Topical, Capsule; Cream - Oral; Topical

Coccidioidomycosis

, 4.0 mg/mL, 10.0 mg/mL, 40.0 mg/mL, 2.0 mg/mL, 50.0 mg, 100.0 mg, 150.0 mg, 200.0 mg, 35.0 mg/mL, 140.0 mg/mL, 0.04 mg/mg, 0.01 mg/mg, 50.0 mg/mL

, Injection, solution, Intravenous, Injection, solution - Intravenous, Oral, Powder, for suspension - Oral, Powder, for suspension, Injection, Injection - Intravenous, Tablet, Tablet - Oral, Capsule, Capsule - Oral, Solution - Intravenous, Solution, Capsule; Cream - Oral; Topical; Vaginal, Oral; Topical; Vaginal, Capsule; Cream, Oral; Topical, Capsule; Cream; Kit - Oral; Topical, Capsule; Cream; Kit, Powder, for solution, Powder, for solution - Oral, Solution - Oral, Solution - Topical, Topical, Capsule; Cream - Oral; Topical

Candida pneumonia

, 4.0 mg/mL, 10.0 mg/mL, 40.0 mg/mL, 2.0 mg/mL, 50.0 mg, 100.0 mg, 150.0 mg, 200.0 mg, 35.0 mg/mL, 140.0 mg/mL, 0.04 mg/mg, 0.01 mg/mg, 50.0 mg/mL

, Injection, solution, Intravenous, Injection, solution - Intravenous, Oral, Powder, for suspension - Oral, Powder, for suspension, Injection, Injection - Intravenous, Tablet, Tablet - Oral, Capsule, Capsule - Oral, Solution - Intravenous, Solution, Capsule; Cream - Oral; Topical; Vaginal, Oral; Topical; Vaginal, Capsule; Cream, Oral; Topical, Capsule; Cream; Kit - Oral; Topical, Capsule; Cream; Kit, Powder, for solution, Powder, for solution - Oral, Solution - Oral, Solution - Topical, Topical, Capsule; Cream - Oral; Topical

Pneumonia

, 4.0 mg/mL, 10.0 mg/mL, 40.0 mg/mL, 2.0 mg/mL, 50.0 mg, 100.0 mg, 150.0 mg, 200.0 mg, 35.0 mg/mL, 140.0 mg/mL, 0.04 mg/mg, 0.01 mg/mg, 50.0 mg/mL

, Injection, solution, Intravenous, Injection, solution - Intravenous, Oral, Powder, for suspension - Oral, Powder, for suspension, Injection, Injection - Intravenous, Tablet, Tablet - Oral, Capsule, Capsule - Oral, Solution - Intravenous, Solution, Capsule; Cream - Oral; Topical; Vaginal, Oral; Topical; Vaginal, Capsule; Cream, Oral; Topical, Capsule; Cream; Kit - Oral; Topical, Capsule; Cream; Kit, Powder, for solution, Powder, for solution - Oral, Solution - Oral, Solution - Topical, Topical, Capsule; Cream - Oral; Topical

Candida (fungus)

, 4.0 mg/mL, 10.0 mg/mL, 40.0 mg/mL, 2.0 mg/mL, 50.0 mg, 100.0 mg, 150.0 mg, 200.0 mg, 35.0 mg/mL, 140.0 mg/mL, 0.04 mg/mg, 0.01 mg/mg, 50.0 mg/mL

, Injection, solution, Intravenous, Injection, solution - Intravenous, Oral, Powder, for suspension - Oral, Powder, for suspension, Injection, Injection - Intravenous, Tablet, Tablet - Oral, Capsule, Capsule - Oral, Solution - Intravenous, Solution, Capsule; Cream - Oral; Topical; Vaginal, Oral; Topical; Vaginal, Capsule; Cream, Oral; Topical, Capsule; Cream; Kit - Oral; Topical, Capsule; Cream; Kit, Powder, for solution, Powder, for solution - Oral, Solution - Oral, Solution - Topical, Topical, Capsule; Cream - Oral; Topical

Candida intertrigo

, 4.0 mg/mL, 10.0 mg/mL, 40.0 mg/mL, 2.0 mg/mL, 50.0 mg, 100.0 mg, 150.0 mg, 200.0 mg, 35.0 mg/mL, 140.0 mg/mL, 0.04 mg/mg, 0.01 mg/mg, 50.0 mg/mL

, Injection, solution, Intravenous, Injection, solution - Intravenous, Oral, Powder, for suspension - Oral, Powder, for suspension, Injection, Injection - Intravenous, Tablet, Tablet - Oral, Capsule, Capsule - Oral, Solution - Intravenous, Solution, Capsule; Cream - Oral; Topical; Vaginal, Oral; Topical; Vaginal, Capsule; Cream, Oral; Topical, Capsule; Cream; Kit - Oral; Topical, Capsule; Cream; Kit, Powder, for solution, Powder, for solution - Oral, Solution - Oral, Solution - Topical, Topical, Capsule; Cream - Oral; Topical

Coccidioidomycosis

, 4.0 mg/mL, 10.0 mg/mL, 40.0 mg/mL, 2.0 mg/mL, 50.0 mg, 100.0 mg, 150.0 mg, 200.0 mg, 35.0 mg/mL, 140.0 mg/mL, 0.04 mg/mg, 0.01 mg/mg, 50.0 mg/mL

, Injection, solution, Intravenous, Injection, solution - Intravenous, Oral, Powder, for suspension - Oral, Powder, for suspension, Injection, Injection - Intravenous, Tablet, Tablet - Oral, Capsule, Capsule - Oral, Solution - Intravenous, Solution, Capsule; Cream - Oral; Topical; Vaginal, Oral; Topical; Vaginal, Capsule; Cream, Oral; Topical, Capsule; Cream; Kit - Oral; Topical, Capsule; Cream; Kit, Powder, for solution, Powder, for solution - Oral, Solution - Oral, Solution - Topical, Topical, Capsule; Cream - Oral; Topical

prophylaxis of moderate Pneumocystis pneumonia

, 4.0 mg/mL, 10.0 mg/mL, 40.0 mg/mL, 2.0 mg/mL, 50.0 mg, 100.0 mg, 150.0 mg, 200.0 mg, 35.0 mg/mL, 140.0 mg/mL, 0.04 mg/mg, 0.01 mg/mg, 50.0 mg/mL

, Injection, solution, Intravenous, Injection, solution - Intravenous, Oral, Powder, for suspension - Oral, Powder, for suspension, Injection, Injection - Intravenous, Tablet, Tablet - Oral, Capsule, Capsule - Oral, Solution - Intravenous, Solution, Capsule; Cream - Oral; Topical; Vaginal, Oral; Topical; Vaginal, Capsule; Cream, Oral; Topical, Capsule; Cream; Kit - Oral; Topical, Capsule; Cream; Kit, Powder, for solution, Powder, for solution - Oral, Solution - Oral, Solution - Topical, Topical, Capsule; Cream - Oral; Topical

Itching

, 4.0 mg/mL, 10.0 mg/mL, 40.0 mg/mL, 2.0 mg/mL, 50.0 mg, 100.0 mg, 150.0 mg, 200.0 mg, 35.0 mg/mL, 140.0 mg/mL, 0.04 mg/mg, 0.01 mg/mg, 50.0 mg/mL

, Injection, solution, Intravenous, Injection, solution - Intravenous, Oral, Powder, for suspension - Oral, Powder, for suspension, Injection, Injection - Intravenous, Tablet, Tablet - Oral, Capsule, Capsule - Oral, Solution - Intravenous, Solution, Capsule; Cream - Oral; Topical; Vaginal, Oral; Topical; Vaginal, Capsule; Cream, Oral; Topical, Capsule; Cream; Kit - Oral; Topical, Capsule; Cream; Kit, Powder, for solution, Powder, for solution - Oral, Solution - Oral, Solution - Topical, Topical, Capsule; Cream - Oral; Topical

prophylaxis of Candida Infections

, 4.0 mg/mL, 10.0 mg/mL, 40.0 mg/mL, 2.0 mg/mL, 50.0 mg, 100.0 mg, 150.0 mg, 200.0 mg, 35.0 mg/mL, 140.0 mg/mL, 0.04 mg/mg, 0.01 mg/mg, 50.0 mg/mL

, Injection, solution, Intravenous, Injection, solution - Intravenous, Oral, Powder, for suspension - Oral, Powder, for suspension, Injection, Injection - Intravenous, Tablet, Tablet - Oral, Capsule, Capsule - Oral, Solution - Intravenous, Solution, Capsule; Cream - Oral; Topical; Vaginal, Oral; Topical; Vaginal, Capsule; Cream, Oral; Topical, Capsule; Cream; Kit - Oral; Topical, Capsule; Cream; Kit, Powder, for solution, Powder, for solution - Oral, Solution - Oral, Solution - Topical, Topical, Capsule; Cream - Oral; Topical

Candida (fungus)

, 4.0 mg/mL, 10.0 mg/mL, 40.0 mg/mL, 2.0 mg/mL, 50.0 mg, 100.0 mg, 150.0 mg, 200.0 mg, 35.0 mg/mL, 140.0 mg/mL, 0.04 mg/mg, 0.01 mg/mg, 50.0 mg/mL

, Injection, solution, Intravenous, Injection, solution - Intravenous, Oral, Powder, for suspension - Oral, Powder, for suspension, Injection, Injection - Intravenous, Tablet, Tablet - Oral, Capsule, Capsule - Oral, Solution - Intravenous, Solution, Capsule; Cream - Oral; Topical; Vaginal, Oral; Topical; Vaginal, Capsule; Cream, Oral; Topical, Capsule; Cream; Kit - Oral; Topical, Capsule; Cream; Kit, Powder, for solution, Powder, for solution - Oral, Solution - Oral, Solution - Topical, Topical, Capsule; Cream - Oral; Topical

Warnings

Fluconazole Contraindications

Condition

Risk Level

Notes

Pulse Frequency

Do Not Combine

Pulse Frequency

Do Not Combine

Pulse Frequency

Do Not Combine

Pulse Frequency

Do Not Combine

Pulse Frequency

Do Not Combine

Pulse Frequency

Do Not Combine

Pulse Frequency

Do Not Combine

Severe Hypersensitivity Reactions

Do Not Combine

Fluconazole may interact with Pulse Frequency

There are 20 known major drug interactions with Fluconazole.

Common Fluconazole Drug Interactions

Drug Name

Risk Level

Description

Abemaciclib

Major

The serum concentration of Abemaciclib can be increased when it is combined with Fluconazole.

Abrocitinib

Major

The metabolism of Abrocitinib can be decreased when combined with Fluconazole.

Acalabrutinib

Major

The metabolism of Acalabrutinib can be decreased when combined with Fluconazole.

Acetylsalicylic acid

Major

The metabolism of Acetylsalicylic acid can be decreased when combined with Fluconazole.

Alectinib

Major

The metabolism of Alectinib can be decreased when combined with Fluconazole.

Fluconazole Toxicity & Overdose Risk

The toxic dose of fluconazole for rats is 1271 mg/kg. Overdosing on fluconazole may cause hallucinations, paranoia, and other stomach related issues. A doctor may recommend flushing out the stomach or dialysis if the drug was taken less than 4 hours prior. People with existing liver issues should be careful when taking fluconazole, as it may worsen the condition. Animal studies have not shown any links to cancer or mutation, but pregnant women should be aware of the potential side effects before taking the drug. Fluconazole is secreted in breastmilk, so caution should be taken when

image of a doctor in a lab doing drug, clinical research

Fluconazole Novel Uses: Which Conditions Have a Clinical Trial Featuring Fluconazole?

37 active trials are currently assessing the utility of Fluconazole in ameliorating Urinary tract infection, Cerebral Cryptococcosis and Coccidioidomycosis.

Condition

Clinical Trials

Trial Phases

prophylaxis of moderate Pneumocystis pneumonia

0 Actively Recruiting

HIV

155 Actively Recruiting

Phase 2, Phase 1, Phase 3, Not Applicable, Phase 4, Early Phase 1

Urinary tract infection

0 Actively Recruiting

Candida (fungus)

0 Actively Recruiting

Pneumonia

0 Actively Recruiting

Bone marrow transplant, cytotoxic chemotherapy

0 Actively Recruiting

Candida (fungus)

0 Actively Recruiting

Peritonitis

0 Actively Recruiting

Cerebral Cryptococcosis

1 Actively Recruiting

Phase 2, Phase 3

Candida intertrigo

0 Actively Recruiting

Oropharyngeal Candidiasis

0 Actively Recruiting

Bone Marrow Transplantation

0 Actively Recruiting

Communicable Diseases

0 Actively Recruiting

Candidemia

4 Actively Recruiting

Phase 3, Phase 2

Candida pneumonia

0 Actively Recruiting

Esophageal Candidiasis

0 Actively Recruiting

prophylaxis of Candida Infections

0 Actively Recruiting

Yeast Infection

0 Actively Recruiting

Itching

2 Actively Recruiting

Phase 3, Not Applicable

Candidiasis

0 Actively Recruiting

Fluconazole Reviews: What are patients saying about Fluconazole?

5

Patient Review

8/16/2022

Fluconazole for Candida Species Yeast Infection of Abdominal Cavity Lining

I don't love the taste, but it's not so bad that I can't get it down. Once you do, this treatment is very effective and doesn't require multiple doses or creams.

4.7

Patient Review

10/21/2022

Fluconazole for Candida Fungus Infection of Mouth, Skin, Nails or Vagina

I completely understand why people might have negative things to say about this treatment, as yeast infections are really awful. However, I found that this pill worked wonders for me and cleared up the infection within a few days.

4.3

Patient Review

5/6/2022

Fluconazole for Candida Species Yeast Infection of Abdominal Cavity Lining

The cheaper, store-brand options didn't work as well for me. Stick to the name brand if you want results.

3.3

Patient Review

12/17/2021

Fluconazole for Thrush

Worked quickly, but I had really bad nausea and vomiting the next night.

3.3

Patient Review

5/26/2022

Fluconazole for Candida Species Yeast Infection of Abdominal Cavity Lining

I had a rash all over my body.

3

Patient Review

1/12/2021

Fluconazole for Ringworm of Scalp

Not a long-term solution, but it helped me in the short term.

2.3

Patient Review

11/29/2021

Fluconazole for Candida Species Yeast Infection of Abdominal Cavity Lining

Unfortunately, I had a lot of negative side effects from this medication including stomach pains and acid reflux. Gas was also an issue. Definitely would not recommend and still experiencing problems even after 5 days have passed.

2

Patient Review

10/27/2021

Fluconazole for Yeast Infection of Vagina and Vulva

I had some really unfortunate side effects after taking this medication- my heart was racing, I felt dizzy and nauseous, and my stomach was in so much pain. This was all after just the first dose of 150mg. I definitely won't be taking this again.

1.3

Patient Review

1/2/2021

Fluconazole for Scattered Infection caused by Coccidioides Fungus

These pills have an incredibly unpleasant taste, to the point where I've gagged or even thrown up trying to take them. The only way I can get them down is by taking them with egg nog from October to February.

1.3

Patient Review

6/4/2021

Fluconazole for Fungal Infection of the Skin with Yellow Patches

The only reason this medicine has such a high rating is because it's easy to take as a pill. I took 300mg for Tinea versicolor and have been incredibly sick since: dizzy, weak, with diarrhea and stomach pain for the last six days. I was supposed to take a second dose but there's no way I'm taking that pill again!

1

Patient Review

9/2/2021

Fluconazole for Thrush

I had a really negative reaction to this treatment. I would urge anyone considering it to read reviews carefully and weigh the pros and cons before making a decision.

1

Patient Review

6/16/2022

Fluconazole for Thrush

Do not use this medication! I experienced chest tightness, difficulty breathing, and high blood pressure after only taking two pills. It's been six days now and I'm still feeling the effects.
image of drug pills surrounding a glass of water symbolizing drug consumption

Patient Q&A Section about fluconazole

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

How long does it take for the fluconazole to work?

"Fluconazole is usually prescribed as a single 150 mg dose for mild, uncomplicated infections. Symptoms usually improve within one to three days."

Answered by AI

What is fluconazole used to treat?

"Fluconazole is an antifungal medication used to treat fungal infections caused by different types of fungi, the most common being a yeast called candida."

Answered by AI

What happens to your body when you take fluconazole?

"Side effects may increase when taking fluconazole with pain drugs such as methadone or fentanyl. These increased side effects can include slower breathing, confusion, and drowsiness."

Answered by AI

Does fluconazole have side effects?

"medical emergency"

Answered by AI

Clinical Trials for Fluconazole

Image of New Jersey Community Research Initiative in Newark, United States.

AI-DBT for Suicide Prevention in HIV/AIDS

18+
All Sexes
Newark, NJ

One in four older persons living with HIV/AIDS (PLWHA) report at least one suicide attempt in their lifetime, and the risk for death by suicide is 100 times higher in PLWHA than in the general population. Currently, there are no behavioral interventions that specifically address suicide prevention for older PLWHA, despite their unique biopsychosocial and structural risk factors. Through this work, investigators will adapt Dialectical Behavior Therapy, an evidence-based intervention for suicide prevention, for patients with PLWHA to be delivered by an AI-powered conversational Agent developed by our industry partner, Empower Health. Investigators will then pilot test the feasibility, usability, acceptability and preliminary efficacy to improve self-efficacy to manage negative emotions in n=50 older adults living with HIV/AIDS.

Recruiting
Has No Placebo

New Jersey Community Research Initiative (+1 Sites)

Elissa Kozlov, PhD

Image of Johns Hopkins Bayview Medical Center in Baltimore, United States.

VR-Enhanced PMR for Post-Burn Symptoms

18+
All Sexes
Baltimore, MD

The goal of this clinical trial is to learn whether progressive muscle relaxation (PMR), delivered either alone or enhanced with virtual reality (VR), can help treat chronic symptom, such as pain, itch, anxiety, sleep disturbances, and fatigue, in adult burn survivors. The main questions it aims to answer are: * Does VR-enhanced PMR (VR-PMR) reduce chronic pain, anxiety, itch, sleep disturbances, and fatigue more effectively than standard PMR? * Is VR-PMR a feasible and acceptable self-administered home-based intervention for burn survivors? Researchers will compare two self-administered intervention conditions, VR-enhanced PMR and standard PMR, using a randomized to sequence crossover design to see if VR technology enhances the therapeutic effects of PMR on chronic symptom management in burn survivors. Participants will: * Complete home-based sessions of VR-enhanced PMR * Complete home-based sessions of standard PMR * Report symptoms such as pain, itch, anxiety, sleep disturbances, and fatigue throughout the study * Use VR equipment provided for the intervention period (during the VR-PMR arm)

Recruiting
Has No Placebo

Johns Hopkins Bayview Medical Center

Sheera Lerman Zohar, PhD

Image of George Washington University Emergency Department in Washington D.C., United States.

Decision Support Tool for HIV Prevention

18+
All Sexes
Washington D.C., United States

This project will explore the development of a personalized decision support tool to assist with pre-exposure prophylaxis (PrEP) initiation and persistence among patients identified in the emergency department (ED) and urgent care settings as PrEP eligible. First, the investigators will use a sequence of validated implementation science methodologies to develop and validate a decision support tool designed to optimize PrEP persistence by strengthening self-efficacy by addressing the multifaceted medical and social needs of the individual patient. The investigators will then test the preliminary effectiveness of this tool through a pilot stepped wedge implementation trial in two EDs and an urgent care in Baltimore, MD and Washington, DC among 120 PrEP eligible patients to determine PrEP initiation, linkage to care, persistence, and adherence rates.

Phase 1
Waitlist Available

George Washington University Emergency Department (+1 Sites)

Image of The University of Alabama at Birmingham in Birmingham, United States.

Behavioral vs Mindfulness Treatments for Insomnia in HIV

50 - 99
All Sexes
Birmingham, AL

The goal of this clinical trial is to examine the effects of a telephone-delivered Brief Behavioral Treatment Insomnia (BBTI) versus a Brief Mindfulness Treatment (BMT) on cognitive and sleep outcomes in older adults with HIV. The main questions it aims to answer are: What are the effects of BBTI vs BMT on self-reported and observed sleep outcomes in older adults with HIV and insomnia up to 1-year post-intervention? What are the effects of BBTI vs BMT on self-reported and observed cognitive comes in older adults with HIV and insomnia up to 1-year post-intervention? What is the association between Alzheimer's Disease biomarkers and sleep and cognitive outcomes in older adults with HIV receiving BBTI vs BMT? Participants will: * Complete 4 weeks of telephone-delivered BBTI or BMT * Attend baseline, post-intervention, and 1-year post in-person visits for sleep and cognitive assessments * Have blood collected at all three time points

Waitlist Available
Has No Placebo

The University of Alabama at Birmingham (+1 Sites)

Dr. Shameka L Cody, PhD, AGNP-C, PMHNP-BC, FAAN

Have you considered Fluconazole clinical trials?

We made a collection of clinical trials featuring Fluconazole, we think they might fit your search criteria.
Go to Trials
Image of Los Angeles General Medical Center in Los Angeles, United States.

Decision Support Tool for HIV Treatment

18+
All Sexes
Los Angeles, CA

This study is testing software designed to help healthcare providers choose the best HIV treatment combinations for their patients. HIV medicines, known as antiretroviral therapy (ART), can be complex to manage because the right regimen depends on many factors-such as drug resistance, other health conditions, and medication schedules. Many people with HIV are cared for by general clinicians who may not have access to HIV specialists, which can make treatment decisions more challenging. In this study, healthcare providers will use patient cases to compare standard HIV treatment resources with a new clinical decision support tool that gives evidence-based ART recommendations at the point of care. The investigators hypothesize that using the tool will help providers select treatment plans that better match clinical guidelines, make decisions faster, reduce mental effort, and increase overall satisfaction with the prescribing process.

Waitlist Available
Has No Placebo

Los Angeles General Medical Center

Hayoun Lee, PhD

Image of University of North Carolina in Chapel Hill, United States.

MGD020 + MGD014 for HIV

18 - 65
All Sexes
Chapel Hill, NC

This research study aims to find out how safe and well tolerated the experimental study drugs are when given to persons with HIV (PWH) taking antiretroviral therapy (ART). The study treatments are MGD014 and MGD020, which are two antibodies developed specifically for HIV, and Vorinostat, an oral medication to help expose HIV in cells to the antibodies. The study will measure the impact of study treatment on non-active HIV in cells, and how long MGD014 and MGD020 stay in the body after they are given. In this study, participants will be randomly assigned to one of three groups. All participants receive MGD014 and MGD020, given sequentially as infusions through an IV for 4 doses. Participants in one group (group A) receive only MGD014 and MGD020. Participants in another group (group B) will stop taking their ART therapy for up to 8 weeks (a temporary treatment interruption (TTI)) while receiving MGD014 and MGD020. Participants in the third group (group C) receive Vorinostat in addition to MGD014 and MGD020. Total time of participation is about 8 months and involves 13 or 18 visits, depending on group assignment.

Phase 1
Recruiting

University of North Carolina

Cynthia L. Gay, MD

Image of Center on Substance Use and Health in San Francisco, United States.

CHAMPION Intervention for Pre-exposure Prophylaxis Adherence

18 - 40
Male
San Francisco, CA

The goal of this randomized controlled trial is to pilot test new mobile health (mHealth) interventions to improve PrEP adherence among HIV-negative men who have sex with men (MSM) with mild to moderate methamphetamine use disorder (MUD). The CHAMPION intervention combines two mHealth tools-PrEPAPP and CBT4CBT-to address both HIV prevention and MUD treatment needs in this population. The study's specific aims are: * To evaluate the feasibility and acceptability of the CHAMPION intervention based on treatment retention and engagement rates. * To examine the preliminary efficacy the CHAMPION intervention to improve PrEP adherence, as measured by dried blood spot (DBS) tests compared to the waitlist control group.

Waitlist Available
Has No Placebo

Center on Substance Use and Health

Glenn-Milo Santos, PhD, MPH

Have you considered Fluconazole clinical trials?

We made a collection of clinical trials featuring Fluconazole, we think they might fit your search criteria.
Go to Trials

Have you considered Fluconazole clinical trials?

We made a collection of clinical trials featuring Fluconazole, we think they might fit your search criteria.
Go to Trials